top-cro-consulting-service-companies-in-europe- Companies

Pharma Tech Outlook: Pharma Tech Magazine

bioskin GmbH: A Skilled Partner For Dermatological Drug Development

Top 10 CRO Consulting/Service Companies in Europe - 2020


Pharmaceutical companies are continually outsourcing their research and development activities—including early-stage research programs— to contract research organisations (CROs) as a means to stay competitive, flexible, and be profitable. Consequently, Europe is emerging as a key location for clinical research as several small-to-midsize CROs are focusing on the region, propelling growth.

Today, several technology-focused CROs are developing in-house expertise, which is altering the global clinical trial paradigm with the implementation of virtual, adaptive, and remote clinical trials. From a business standpoint, CROs are moving toward an embedded model by integrating their services with the sponsor’s business strategy, thereby supporting pharma companies as their end-to-end solution provider.

Even CROs are now expanding their addressable market by increasing the breadth and depth of solutions across the entire drug development lifecycle. They are investing in big data and leveraging data from wearable medical devices to improve the quality of data and efficiency of trails.

At this juncture, many cutting-edge CRO consulting/ service companies are entering the domain with advanced and integrated offerings. To help the pharmaceutical sector strengthen its operational capabilities and simultaneously enable growth in the industry, Pharma Tech Outlook has compiled this edition. The list comprises prominent organisations that are addressing issues pertinent to the pharma sector by implementing current trends. Besides, the magazine also includes insights from thought leaders in the sector on the industry trends, best practices, recent innovations, and their advice for the aspiring CIOs.

We present to you Pharma Tech Outlook’s, “Top 10 CRO Consulting/Service Companies in Europe - 2020.”

    Top CRO Consulting/Service Companies in Europe

  • Biomedcode is a highly innovative Contract Research Organization (CRO) offering a diverse array of advanced pre-clinical evaluation platforms based on a unique collection of spontaneous and induced mouse disease models humanized for TNF, TNFR1, RANKL, IL17A and IL23p19 closely recapitulating the complexity of human inflammatory diseases including arthritis, spondyloarthritis, osteoporosis, psoriasis, multiple sclerosis and others. The company maintains a highly active R&D programme aiming to generate and standardise novel humanised disease models to be used as pre-clinical evaluation platforms as well as tools for the study of disease mechanisms

  • A full-service CRO offering global dermatologic consulting and all services for the management of Phase I-IV drug trials and claim support/safety studies

  • Blueclinical provides all the critical conditions necessary for the success of a clinical research project. The company offers first-in-human (FIH) single and multiple-dose escalation, PoC studies, bioavailability/bioequivalence research, and drug-drug interactions among many other services. It maintains a database of more than 8500 healthy volunteers alongside a highly-qualified team of over 120 employees that include doctors who specialise in various disciplines. Leveraging the collective experiences of such a strong workforce, the company is able to support researchers to adhere to the many international regulations while delivering a full-fledged product. The company’s services include the BlueClinical Phase I operations as well as R&D consultancy services and clinical research partnership

  • Cardialysis conducts clinical trials to investigate pharmaceutical and device therapies used in coronary heart disease or structural heart disease, where interventional device therapies are offered in hospital catheterization laboratories. The company has emerged as the epicenter of cardiovascular innovation, connecting sponsors and investigational sites in sponsor-driven studies, and linking grant-givers, steering committees, and investigational sites in investigator-initiated studies. Besides expanding its footprint in heart failure trials, the company is striving to offer its services at a lower cost to counter the COVID-19 effect while exploring new ways to improve innovation outcomes in multi-CRO projects

  • EphyX Neuroscience is a CRO specialized in in vitro (acute slices) electrophysiology applied to the early CNS-related preclinical phases and drug discovery. The company aims to quickly and efficiently help its clients optimize their compound selection to limit the risk of failure. With highly qualified experts performing recordings in acute slices from both rodent and human, makes EphyX Neuroscience’s data truely predictive. Additionally, EphyX propose both pre-designed packages tackling key aspects of selected conditions and on-demand services to address client-specific needs and assess mechanistic details of their compound's action. We partner with an innovative in vivo platform on site, providing key complementary in vivo data which, together with our in vitro specialization, offers a rare oportunity to boost CNS pre-clinical drug discovery

  • Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials.With its two-commercial specialistCRO services businesses—hVIVO and Venn Life Sciences—Open Orphan is uniquely positioned to help scientists and medics assess the effectiveness of vaccines or treatments against the disease and identify any side effects. Led by a highly experienced Board and management team with deep industry and financial experience and a track record of delivering shareholder value, Open Orphan brings a rich history of commercial human challenge studies to the table.Open Orphan takes immense pride in having commenced the development of the world’s first human Coronavirus challenge study model in March 2020

  • Porsolt is a long-established preclinical CRO, that has obtained an international reputation for expertise in physiopathological models, customized procedures and tailored solutions for discovering treatments of psychiatric and neurological disorders, acute and chronic pain, inflammation, cardiac and vascular diseases, and metabolic and eating disorders. The company also offers services for safety evaluation of drug candidates from screening to pre-Phase 1 regulatory studies (ICH S7), in full compliance with GLP. Porsolt’s safety program includes full assessment of arrhythmogenic risk and abuse/dependence liability

  • With more than 30 years of experience in conducting POC and efficacy studies from lead finding to functional in vitro assays to transgenic and non-transgenic in vivo disease models, QPS operates as a trusted company to carry out neurodegeneration research. The company was founded as a spin-off of an AT pharma company, which gained licensing in the early 2000s. The global research organisation offers an extensive range of validated transgenic and non-transgenic in vivo and in vitro models for neurodegenerative and rare diseases such as Alzheimer’s, Parkinson’s, Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Niemann-Pick Disease (NPC1), Gaucher Disease, Autism Spectrum Disorder, and Schizophrenia among others

  • CTG


    A regional Contract Research Organization (CRO) experienced and specialized in clinical studies with operations in Eastern Europe and Romania

  • Medicorent


    Medicorent Int. AB is a full-service CRO Alliance, built through partnerships between carefully selected companies offering state of the art consulting services and IT-solutions. Through the alliance, Medicorent offers end to end clinical development services under one umbrella as well as strategic regulatory advice and supportive services including outsourcing & recruitments.The alliance offers flexible service models and long-term relations, fulfilling previously unmet multi-faceted need for start-ups and mid-size pharma-, biotech & medtech companies